Glaukos Corp - Understand $gkos stock

$GKOS Market Cap: $7.624 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$360.3M

TTM

Gross Margin

76.62%

TTM

Net Earnings

-$149.6M

TTM

Current Assets

$397.3M

Q3 2024

Current Liabilities

$71.68M

Q3 2024

Current Ratio

554.21%

Q3 2024

Total Assets

$926.5M

Q3 2024

Total Liabilities

$258.0M

Q3 2024

Book Value

$668.5M

Q3 2024

Cash

$100.1M

Q3 2024

P/E

-50.97

Nov 29, 2024 EST

Free Cash Flow

-$81.28M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$314.7M	$282.9M	$294.0M	$225.0M	$237.0M	$181.3M	$159.3M	$114.4M	$71.70M	$45.60M	$20.90M	$2.400M
YoY Change	11.26%	-3.79%	30.7%	-5.07%	30.73%	13.83%	39.21%	59.55%	57.24%	118.18%	770.83%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$314.7M	$282.9M	$294.0M	$225.0M	$237.0M	$181.3M	$159.3M	$114.4M	$71.70M	$45.60M	$20.90M	$2.400M
Cost Of Revenue	$75.58M	$68.98M	$66.63M	$91.72M	$38.59M	$25.08M	$21.05M	$16.20M	$13.00M	$11.40M	$2.500M	$1.700M
Gross Profit	$239.1M	$213.9M	$227.4M	$133.2M	$198.4M	$156.2M	$138.2M	$98.20M	$58.70M	$34.20M	$18.40M	$800.0K
Gross Profit Margin	75.99%	75.61%	77.34%	59.23%	83.72%	86.17%	86.78%	85.84%	81.87%	75.0%	88.04%	33.33%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$224.1M	$192.9M	$179.3M	$171.4M	$176.6M	$119.5M	$96.26M	$64.80M	$44.00M	$28.10M	$17.10M	$9.600M
YoY Change	16.14%	7.62%	4.58%	-2.96%	47.78%	24.17%	48.55%	47.27%	56.58%	64.33%	78.13%
% of Gross Profit	93.7%	90.2%	78.83%	128.64%	89.03%	76.52%	69.65%	65.99%	74.96%	82.16%	92.93%	1200.0%
Research & Development	$138.8M	$123.3M	$101.0M	$85.39M	$68.31M	$49.68M	$38.91M	$29.20M	$25.00M	$19.20M	$15.50M	$13.30M
YoY Change	12.57%	22.05%	18.28%	25.01%	37.51%	27.69%	33.24%	16.8%	30.21%	23.87%	16.54%
% of Gross Profit	58.03%	57.63%	44.42%	64.09%	34.43%	31.8%	28.15%	29.74%	42.59%	56.14%	84.24%	1662.5%
Depreciation & Amortization	$33.65M	$31.58M	$29.66M	$29.38M	$6.306M	$6.264M	$5.482M	$4.720M	$4.270M	$4.230M	$1.160M	$640.0K
YoY Change	6.58%	6.46%	0.95%	365.92%	0.67%	14.26%	16.14%	10.54%	0.95%	264.66%	81.25%
% of Gross Profit	14.07%	14.76%	13.04%	22.05%	3.18%	4.01%	3.97%	4.81%	7.27%	12.37%	6.3%	80.0%
Operating Expenses	$367.8M	$296.2M	$260.3M	$256.8M	$248.7M	$169.2M	$140.5M	$94.00M	$69.00M	$47.40M	$32.60M	$22.80M
YoY Change	24.19%	13.81%	1.35%	3.26%	46.97%	20.44%	49.45%	36.23%	45.57%	45.4%	42.98%
Operating Profit	-$128.7M	-$82.31M	-$32.87M	-$123.6M	-$50.29M	-$13.00M	-$2.281M	$4.200M	-$10.30M	-$13.20M	-$14.20M	-$22.00M
YoY Change	56.35%	150.4%	-73.39%	145.67%	286.8%	470.01%	-154.31%	-140.78%	-21.97%	-7.04%	-35.45%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$13.63M	$13.72M	$13.37M	$14.12M	$2.565M	$2.300M	$2.300M	$900.0K	-$1.100M	$0.00	$300.0K	$300.0K
YoY Change	-0.63%	2.6%	-5.26%	450.29%	11.52%	0.0%	155.56%	-181.82%		-100.0%	0.0%
% of Operating Profit								21.43%
Other Income/Expense, Net	-$5.027M	-$16.12M	-$16.40M	-$8.761M	$256.0K	$634.0K	$2.282M	-$600.0K	-$1.100M	-$900.0K	-$300.0K	-$200.0K
YoY Change	-68.81%	-1.7%	87.14%	-3522.27%	-59.62%	-72.22%	-480.33%	-45.45%	22.22%	200.0%	50.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$133.7M	-$98.43M	-$49.27M	-$132.3M	-$50.04M	-$12.37M	$1.000K	$4.600M	-$38.30M	-$14.00M	-$14.20M	-$22.00M
YoY Change	35.86%	99.79%	-62.77%	164.44%	304.56%	-1236900.0%	-99.98%	-112.01%	173.57%	-1.41%	-35.45%
Income Tax	$934.0K	$766.0K	$326.0K	-$11.97M	-$65.46M	$583.0K	$93.00K	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income							9300.0%	0.0%
Net Earnings	-$134.7M	-$99.20M	-$49.59M	-$120.3M	$15.42M	-$12.95M	-$92.00K	$4.500M	-$37.20M	-$12.10M	-$12.60M	-$19.30M
YoY Change	35.79%	100.02%	-58.79%	-880.26%	-219.1%	13977.17%	-102.04%	-112.1%	207.44%	-3.97%	-34.72%
Net Earnings / Revenue	-42.8%	-35.07%	-16.87%	-53.5%	6.51%	-7.14%	-0.06%	3.93%	-51.88%	-26.54%	-60.29%	-804.17%
Basic Earnings Per Share	-$2.78	-$2.09	-$1.07	-$2.70	$0.41	-$0.37	$0.00
Diluted Earnings Per Share	-$2.78	-$2.09	-$1.07	-$2.70	$0.37	-$0.37	$0.00	$123.3K	-$2.126M	-$407.4K	-$424.2K	-$649.8K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$295.4M	$352.7M	$414.1M	$404.4M	$174.0M	$140.5M	$119.0M	$95.80M	$91.10M	$2.300M	$6.700M	$1.700M
YoY Change	-16.24%	-14.82%	2.39%	132.41%	23.84%	18.07%	24.22%	5.16%	3860.87%	-65.67%	294.12%
Cash & Equivalents	$93.47M	$119.5M	$100.7M	$96.60M	$62.40M	$29.80M	$24.50M	$6.500M	$21.60M	$2.300M	$6.700M	$1.700M
Short-Term Investments	$202.0M	$233.2M	$313.3M	$307.8M	$111.6M	$110.7M	$94.50M	$89.30M	$69.60M
Other Short-Term Assets	$18.19M	$17.25M	$15.63M	$13.20M	$7.900M	$4.100M	$2.600M	$3.100M	$1.400M	$600.0K	$500.0K	$400.0K
YoY Change	5.47%	10.39%	18.38%	67.09%	92.68%	57.69%	-16.13%	121.43%	133.33%	20.0%	25.0%
Inventory	$41.99M	$37.84M	$23.01M	$15.80M	$42.60M	$13.30M	$11.20M	$6.800M	$4.100M	$2.300M	$1.900M	$900.0K
Prepaid Expenses
Receivables	$39.85M	$36.07M	$33.44M	$36.10M	$38.40M	$18.70M	$16.70M	$14.30M	$7.500M	$5.400M	$2.900M	$600.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$395.5M	$443.9M	$486.1M	$469.4M	$262.9M	$176.6M	$149.5M	$120.0M	$104.1M	$10.60M	$12.00M	$3.500M
YoY Change	-10.9%	-8.69%	3.56%	78.55%	48.87%	18.13%	24.58%	15.27%	882.08%	-11.67%	242.86%
Property, Plant & Equipment	$174.5M	$166.8M	$146.1M	$95.50M	$91.80M	$19.20M	$11.80M	$7.600M	$2.200M	$2.000M	$1.900M	$1.600M
YoY Change	4.62%	14.16%	53.02%	4.03%	378.13%	62.71%	55.26%	245.45%	10.0%	5.26%	18.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$21.33M	$17.69M	$18.52M	$16.80M	$15.00M	$11.00M	$1.400M	$200.0K	$100.0K	$0.00	$100.0K	$0.00
YoY Change	20.54%	-4.5%	10.26%	12.0%	36.36%	685.71%	600.0%	100.0%		-100.0%
Total Long-Term Assets	$545.0M	$558.5M	$563.6M	$536.1M	$555.5M	$30.40M	$16.30M	$14.40M	$12.60M	$15.40M	$18.90M	$1.700M
YoY Change	-2.43%	-0.9%	5.12%	-3.49%	1727.3%	86.5%	13.19%	14.29%	-18.18%	-18.52%	1011.76%
Total Assets	$940.4M	$1.002B	$1.050B	$1.006B	$818.4M	$207.0M	$165.8M	$134.4M	$116.7M	$26.00M	$30.90M	$5.200M
YoY Change
Accounts Payable	$13.44M	$14.40M	$7.333M	$4.400M	$5.800M	$6.300M	$6.200M	$3.000M	$3.600M	$3.300M	$3.300M	$2.100M
YoY Change	-6.69%	96.41%	66.66%	-24.14%	-7.94%	1.61%	106.67%	-16.67%	9.09%	0.0%	57.14%
Accrued Expenses	$60.57M	$57.96M	$56.03M	$45.30M	$51.90M	$24.00M	$20.40M	$13.90M	$7.800M	$6.500M	$2.100M	$1.500M
YoY Change	4.52%	3.44%	23.68%	-12.72%	116.25%	17.65%	46.76%	78.21%	20.0%	209.52%	40.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.900M	$0.00	$10.50M
YoY Change									-100.0%		-100.0%
Long-Term Debt Due								$0.00	$8.900M	$8.500M	$0.00	$0.00
YoY Change								-100.0%	4.71%
Total Short-Term Liabilities	$74.01M	$72.36M	$63.36M	$49.70M	$57.70M	$30.40M	$26.80M	$16.90M	$20.40M	$20.20M	$5.500M	$14.10M
YoY Change	2.29%	14.2%	27.48%	-13.86%	89.8%	13.43%	58.58%	-17.16%	0.99%	267.27%	-60.99%
Long-Term Debt	$353.3M	$353.6M	$352.7M	$250.1M	$58.40M	$0.00	$0.00	$0.00	$800.0K	$9.000M	$17.50M	$0.00
YoY Change	-0.07%	0.24%	41.03%	328.25%				-100.0%	-91.11%	-48.57%
Other Long-Term Liabilities	$44.18M	$39.18M	$39.14M	$27.70M	$19.40M	$2.700M	$800.0K	$200.0K	$300.0K	$400.0K	$700.0K	$1.000M
YoY Change	12.75%	0.1%	41.31%	42.78%	618.52%	237.5%	300.0%	-33.33%	-25.0%	-42.86%	-30.0%
Total Long-Term Liabilities	$397.5M	$392.8M	$391.9M	$277.8M	$77.80M	$2.700M	$800.0K	$200.0K	$1.100M	$9.400M	$18.20M	$1.000M
YoY Change	1.21%	0.23%	41.06%	257.07%	2781.48%	237.5%	300.0%	-81.82%	-88.3%	-48.35%	1720.0%
Total Liabilities	$478.6M	$472.4M	$462.5M	$338.1M	$145.1M	$33.10M	$27.60M	$17.10M	$21.50M	$19.90M	$16.00M	$9.000M
YoY Change	1.33%	2.13%	36.81%	133.01%	338.37%	19.93%	61.4%	-20.47%	8.04%	24.38%	77.78%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Basic Shares Outstanding	48.43M	47.44M	46.42M	44.50M	37.36M	35.32M	34.38M	32.93M
Diluted Shares Outstanding	48.43M	47.44M	46.42M	44.50M	41.15M	35.32M	34.38M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $7.6239 Billion

About GLAUKOS Corp

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 907 full-time employees. The company went IPO on 2015-06-25. The company develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES AtriCure, Inc. Axonics, Inc. Enovis CORP CONMED Corp Integer Holdings Corp INTEGRA LIFESCIENCES HOLDINGS CORP NUVASIVE INC PROCEPT BioRobotics Corp TANDEM DIABETES CARE INC